The first speaker was Professor Dr Leong Chee Onn, from the School of Pharmacy and Health Sciences, Department of Life Sciences, International Medical University, Malaysia and Deputy Director (Research), Institute for Research, Development and Innovation, International Medical University, Malaysia. Prof. Dr Leong shared the work done by his group on the targeting of breast cancer stem cells by using high-throughput chemical library screening.
Following this, Dr Kyaw Toe, staff surgeon at the Breast Unit at North Tees and Hartlepool NHS Trust, shared the experience of his institution in terms of breast conserving surgery. Dr Kyaw talked about the principles of breast conserving surgery and how it was done in the past and the current practice.
Finally, Clinical Associate Professor Dr Myo Oo, from the Department of Population Medicine, Faculty of Medicine & Health Sciences, Universiti Tunku Abdul Rahman, talked about implementation research and its importance in breast cancer research.
A Q&A session followed the talk where each speaker took turns to answer some questions from the participants. The Q&A session was moderated by Associate Professor Dr Leong Pooi Pooi and Dr Fann Rui Jeat.
Missed out the webinar entitled "Stem Cells: From Bench to Clinic"?
Just click to view the videos:
(1) Prof. Chua, as you are engaged in lab works, do you still treat patients in the hospital as a urologist?
(2) How long does it take to generate an organoid and also the maintenance too?
(3) How thick is an organoid formed from under the surface of culture? In drug testing, how do you ensure drugs given are exposed to all organoids at different layers of thickness?
(4) Could you please share your experience on organoid culture for first-timer?
(1) I would like to know your opinion on MSC differentiated from iPSCs. Can these MSCs-iPSCs replace the actual MSCs in clinical therapy?
(2) Since MSC has limitation as there are possibilities of pro-tumour activity, would you mind to share on how to ensure the MSC treatment will not trigger this?
(3) I am wondering, have you guys thought of using MSC to co-culture with cancer to assess whether 1. If the cancer would promote the differentiation of MSC into cancer associated fibroblast or 2. If they could suppress the growth of the cancer cells?
(1) Have you tried to generate a specific type of cancer from iPSC?
(2) Do you think the loss of tumorigenicity of cancer upon reprogrammed into iPSC is something to do with the switching of tumor cells back into more "normal state"?
(3) Could these "iPSCs" remove the tumor cells in the tumor microenvironment?
(4) Since you are generating cancer-derived iPSC, what do you think of cancer-derived iPSC potential in research or in clinical study?
(1) For the use of MSC to treat various pathological conditions, once the patients show an improvement, would you guys continue injecting MSC to the patients to further improve the condition? When you stop treating the patients, would the pathological condition appear again?
(2) Can you share how you scale up the MSC numbers for clinical usage? As we know, MSC can be hampered by their limited proliferative rate.
(1) What would be the major advantage of using iPSC compared to MSC?
your opinion, how much can the MSC-iPSC can differ from the actual MSC? In
terms of morphology and the expressions?